Do SGLT2 inhibitors have a protective effect against Doxorubicin-induced heart failure in mice?
SGLT2 inhibitors demonstrate cardioprotective effects in a mouse model of doxorubicin-induced heart failure, suggesting potential utility in non-diabetic heart failure.
SGLT2 inhibitors have a protective effect in Dox-induced HF in mice. This implied that SGLT2 inhibitor therapy could be a good treatment strategy even in HF patients without diabetes.
Oh et al. (Tue,) studied this question.